SG11202107886RA - Cyclic molecules as bruton's tyrosine kinase inhibitor - Google Patents

Cyclic molecules as bruton's tyrosine kinase inhibitor

Info

Publication number
SG11202107886RA
SG11202107886RA SG11202107886RA SG11202107886RA SG11202107886RA SG 11202107886R A SG11202107886R A SG 11202107886RA SG 11202107886R A SG11202107886R A SG 11202107886RA SG 11202107886R A SG11202107886R A SG 11202107886RA SG 11202107886R A SG11202107886R A SG 11202107886RA
Authority
SG
Singapore
Prior art keywords
bruton
tyrosine kinase
kinase inhibitor
cyclic molecules
cyclic
Prior art date
Application number
SG11202107886RA
Other languages
English (en)
Inventor
Zhaoyin Wang
Bing Yao
Yuanshan Yao
Ao Li
Prabhakar Kondaji Jadhav
Guoqing Cao
Original Assignee
Minghui Pharmaceutical Shanghai Ltd
Minghui Pharmaceutical Hangzhou Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minghui Pharmaceutical Shanghai Ltd, Minghui Pharmaceutical Hangzhou Ltd filed Critical Minghui Pharmaceutical Shanghai Ltd
Publication of SG11202107886RA publication Critical patent/SG11202107886RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202107886RA 2019-01-18 2020-01-16 Cyclic molecules as bruton's tyrosine kinase inhibitor SG11202107886RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910049183.9A CN111454268B (zh) 2019-01-18 2019-01-18 作为布鲁顿酪氨酸激酶抑制剂的环状分子
PCT/CN2020/072551 WO2020147798A1 (fr) 2019-01-18 2020-01-16 Molécules cycliques servant d'inhibiteur de la tyrosine kinase de bruton

Publications (1)

Publication Number Publication Date
SG11202107886RA true SG11202107886RA (en) 2021-08-30

Family

ID=71613532

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107886RA SG11202107886RA (en) 2019-01-18 2020-01-16 Cyclic molecules as bruton's tyrosine kinase inhibitor

Country Status (13)

Country Link
US (1) US20220081445A1 (fr)
EP (1) EP3912980A4 (fr)
JP (2) JP7436994B2 (fr)
KR (1) KR20210135497A (fr)
CN (3) CN111454268B (fr)
AU (1) AU2020208128B2 (fr)
BR (1) BR112021014100A2 (fr)
CA (1) CA3129841C (fr)
EA (1) EA202191995A1 (fr)
IL (1) IL284916A (fr)
MX (1) MX2021008632A (fr)
SG (1) SG11202107886RA (fr)
WO (1) WO2020147798A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020419422A1 (en) * 2020-01-02 2022-06-02 Dizal (Jiangsu) Pharmaceutical Co., Ltd. BTK inhibitors
CN113943294A (zh) * 2020-07-15 2022-01-18 成都海博为药业有限公司 一种作为btk抑制剂的化合物及其制备方法与用途
CN114573586B (zh) * 2020-11-28 2023-11-03 杭州和正医药有限公司 一种抑制布鲁顿酪氨酸激酶活性的多环化合物、药物组合物及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
ATE247657T1 (de) * 1999-09-17 2003-09-15 Basf Ag Pyrazolopyrimidine als arzneimittel
JP2007520559A (ja) * 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
WO2007075554A2 (fr) * 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Traitement combine avec une composition d’inhibiteur de proteine kinase heterobicyclique a noyau 6,6-bicyclique et d'agents anticancereux
CN102887900B (zh) * 2006-09-22 2015-04-29 药品循环公司 布鲁顿酪氨酸激酶的抑制剂
SG10201508035TA (en) * 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
EP3311818A3 (fr) * 2008-07-16 2018-07-18 Pharmacyclics, LLC Inhibiteurs de tyrosine-kinase de bruton pour le traitement de tumeurs solides
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
JP2014520863A (ja) * 2011-07-13 2014-08-25 ファーマサイクリックス，インク． Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
EP2548877A1 (fr) * 2011-07-19 2013-01-23 MSD Oss B.V. Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK
JP6114296B2 (ja) * 2011-11-08 2017-04-12 インテリカイン， エルエルシー 複数の医薬品を使用した治療レジメン
CN104080789B (zh) * 2012-01-31 2016-05-11 南京奥昭生物科技有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
RU2678767C2 (ru) * 2012-05-31 2019-02-01 ГБ005, Инк. Ингибиторы протеинкиназ
AU2013277582B2 (en) * 2012-06-18 2017-11-30 Principia Biopharma Inc. Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
CA2934989C (fr) * 2014-02-03 2017-08-08 Cadila Healthcare Limited Nouveaux composes heterocycliques
CN105017256A (zh) * 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
US9580416B2 (en) * 2014-07-02 2017-02-28 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
CA2959602A1 (fr) * 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibiteurs de la tyrosine kinase de bruton
TW201613926A (en) * 2014-08-01 2016-04-16 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CA2998796A1 (fr) * 2015-09-16 2017-03-23 Loxo Oncology, Inc. Derives de pyrazolopyrimidine comme inhibiteurs de btk pour le traitement du cancer
CN105732638B (zh) * 2016-01-22 2018-01-30 成都倍特药业有限公司 一种具有螺环或桥环结构的布鲁顿酪氨酸激酶抑制剂及其制备方法
CN107344940B (zh) * 2016-05-06 2020-04-21 广东东阳光药业有限公司 Btk抑制剂及其用途
CN109153680B (zh) * 2016-07-07 2021-04-23 株式会社大熊制药 4-氨基吡唑并[3,4-d]嘧啶基氮杂双环衍生物及含其的药物组合物
US10865208B2 (en) * 2016-11-11 2020-12-15 Millennium Pharmaceuticals, Inc. ATG7 inhibitors and the uses thereof
GB201705971D0 (en) * 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
CN107827892A (zh) * 2017-10-27 2018-03-23 上海应用技术大学 一种非受体酪氨酸激酶小分子抑制剂及其应用

Also Published As

Publication number Publication date
EP3912980A4 (fr) 2022-12-07
JP2022523480A (ja) 2022-04-25
US20220081445A1 (en) 2022-03-17
MX2021008632A (es) 2021-10-26
EP3912980A1 (fr) 2021-11-24
JP7436994B2 (ja) 2024-02-22
KR20210135497A (ko) 2021-11-15
CA3129841C (fr) 2023-09-26
CN111454268A (zh) 2020-07-28
CN116589465A (zh) 2023-08-15
JP2023179562A (ja) 2023-12-19
CN111454268B (zh) 2023-09-08
BR112021014100A2 (pt) 2021-09-21
EA202191995A1 (ru) 2021-11-18
AU2020208128A1 (en) 2021-09-09
IL284916A (en) 2021-09-30
CN113710671A (zh) 2021-11-26
WO2020147798A1 (fr) 2020-07-23
CN113710671B (zh) 2023-04-28
CA3129841A1 (fr) 2020-07-23
AU2020208128B2 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
ZA201903932B (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
IL255831A (en) Inhibitors of bruton's tyrosine kinase
EP3414234A4 (fr) Inhibiteurs de la tyrosine kinase de bruton
EP3572414A4 (fr) Composé utilisé comme inhibiteur de la tyrosine kinase de bruton, son procédé de préparation et son application
IL274716A (en) Synthesis of a proton tyrosine kinase inhibitor
ZA201805439B (en) Bruton's tyrosine kinase inhibitors
IL253995A0 (en) Pharmaceutical formulations of proton tyrosine kinase inhibitor
ZA201906887B (en) Bruton's tyrosine kinase inhibitors
IL284916A (en) Cyclic molecules as Bruton's tyrosine kinase inhibitors
MY179781A (en) Biaryl inhibitors of bruton's tyrosine kinase
IL259863B (en) Polycyclic compounds as inhibitors of proton tyrosine kinase
ZA201805951B (en) Compounds and methods for modulating bruton's tyrosine kinase
HK1258699A1 (zh) 包含酪氨酸蛋白激酶抑制劑的劑型組合物
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
PT3609886T (pt) Análogos de benzoazepina como agentes inibidores para tirosina quinase de bruton
EP3328380A4 (fr) Combinaisons d'inhibiteur de la tyrosine kinase de bruton et leurs utilisations
EP3882241A4 (fr) Inhibiteur de la tyrosine kinase de bruton
EP3412657A4 (fr) Nouvel inhibiteur irréversible de la tyrosine kinase de bruton
EP3966204A4 (fr) 1-amino-1h-imidazole-5-carboxamide substitué utilisé en tant qu'inhibiteurs de la tyrosine kinase de bruton
EP4069689A4 (fr) Imidazolecarboxamide substitué utilisé comme inhibiteurs de la tyrosine kinase de bruton
MA55964A (fr) Agents inhibiteurs de la tyrosine kinase de bruton